VacV002 / VacV Biotherap - LARVOL DELTA

VacV Exits Stealth Mode to Advance Cancer Immunotherapies - "U.K. startup VacV Biotherapeutics has emerged from stealth mode as it stands poised to bring its novel viral-based cancer therapies into clinical development. The spin out from Barts Cancer Institute and Queen Mary University of London uses immunotherapy based on a genetically modified version of the Vaccinia virus to stimulate the immune system while at the same time destroying cancer cells....Its development program includes VacV001 for pancreatic cancer and glioblastoma and VacV002 for colorectal cancer with liver metastasis, both of which are nearing the end of preclinical development. The cancer immunotherapy company predicts that its most advanced programs will be set to enter clinical trials over the next few years."

Clinical • Colorectal Cancer • Gastrointestinal Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor